Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Chromatin accessibility at the HIV LTR promoter sets a threshold for NF-κB mediated viral gene expression.

Miller-Jensen K, Dey SS, Pham N, Foley JE, Arkin AP, Schaffer DV.

Integr Biol (Camb). 2012 Jun;4(6):661-71. doi: 10.1039/c2ib20009k. Epub 2012 May 3.


Control of stochastic gene expression by host factors at the HIV promoter.

Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV.

PLoS Pathog. 2009 Jan;5(1):e1000260. doi: 10.1371/journal.ppat.1000260. Epub 2009 Jan 9.


Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1.

Williams SA, Kwon H, Chen LF, Greene WC.

J Virol. 2007 Jun;81(11):6043-56. Epub 2007 Mar 21.


Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB.

Ying H, Zhang Y, Zhou X, Qu X, Wang P, Liu S, Lu D, Zhu H.

PLoS One. 2012;7(11):e48832. doi: 10.1371/journal.pone.0048832. Epub 2012 Nov 15.


Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies.

Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, Berkhout B, Castellano R, de Launoit Y, Burny A, Piette J, Bours V, Van Lint C.

J Virol. 2002 Nov;76(21):11091-103.


Association of p65 and C/EBPbeta with HIV-1 LTR modulates transcription of the viral promoter.

Mukerjee R, Sawaya BE, Khalili K, Amini S.

J Cell Biochem. 2007 Apr 1;100(5):1210-6.


Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter.

El Kharroubi A, Piras G, Zensen R, Martin MA.

Mol Cell Biol. 1998 May;18(5):2535-44.


Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency.

Kim YK, Bourgeois CF, Pearson R, Tyagi M, West MJ, Wong J, Wu SY, Chiang CM, Karn J.

EMBO J. 2006 Aug 9;25(15):3596-604. Epub 2006 Jul 27.


NF-kappa B subunit-specific regulation of the interleukin-8 promoter.

Kunsch C, Rosen CA.

Mol Cell Biol. 1993 Oct;13(10):6137-46.


NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.

Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC.

EMBO J. 2006 Jan 11;25(1):139-49. Epub 2005 Dec 1.


Stimulation of HIV type 1 gene expression and induction of NF-kappa B (p50/p65)-binding activity in tumor necrosis factor alpha-treated human fetal glial cells.

Atwood WJ, Tornatore CS, Traub R, Conant K, Drew PD, Major EO.

AIDS Res Hum Retroviruses. 1994 Oct;10(10):1207-11.


NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro.

Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT, Jones KA.

Genes Dev. 1996 Jan 1;10(1):37-49.


Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat.

Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J.

Mol Cell Biol. 2014 Jun;34(11):1911-28. doi: 10.1128/MCB.01013-13. Epub 2014 Mar 17.


Interaction between cell cycle regulator, E2F-1, and NF-kappaB mediates repression of HIV-1 gene transcription.

Kundu M, Guermah M, Roeder RG, Amini S, Khalili K.

J Biol Chem. 1997 Nov 21;272(47):29468-74.


Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.

Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A.

J Biol Chem. 2007 Sep 28;282(39):28408-18. Epub 2007 Aug 3.

Supplemental Content

Support Center